Drug Type Unknown |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Solve Therapeutics, Inc.Startup |
Active Organization Solve Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Endometrial Carcinoma | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Metastatic breast cancer | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Metastatic Carcinoma to the Uterine Cervix | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Metastatic Solid Tumor | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Non-Small Cell Lung Cancer | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Ovarian Cancer | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Sarcoma | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Small Cell Lung Cancer | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |
Transitional Cell Carcinoma | Phase 1 | - | Solve Therapeutics, Inc.Startup | 01 Apr 2025 |